A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.
Liu D, Qi X, Wei X, Zhao L, Wang X, Li S, Wang Z, Shi L, Xu J, Hong M, Liu Z, Zhao L, Wang X, Zhang B, Zhang Y, Wang F, Cao YJ.
Liu D, et al. Among authors: liu z.
Theranostics. 2022 Nov 14;12(18):7788-7803. doi: 10.7150/thno.75037. eCollection 2022.
Theranostics. 2022.
PMID: 36451856
Free PMC article.